President Donald Trump’s first budget has not gone down well with the medical research and regulatory communities, which have come out against his plans to cut…

Seres Therapeutics has unveiled the design of a phase 2 trial it thinks could secure FDA approval for its microbiome drug.

Astex Pharmaceuticals has pocketed a milestone payment from Novartis after the latter's cancer drug secured FDA approval.

Karyopharm has seen studies for its big hope selinexor placed on a partial clinical hold, meaning it can no longer recruit new patients, over the FDA’s demands…

Ionis saw its share price fall 8% after it posted results from a phase 3 trial of its antisense drug volanesorsen in familial chylomicronemia syndrome.

Advaxis and Amgen get an FDA OK to start testing their neoantigen cancer vaccine, partnered in a $540 million deal last year.

Sanofi and Regeneron have taken a deeper dive into phase 3 data on hotly tipped atopic dermatitis drug dupilumab.

Shares in Scynexis went into a tailspin yesterday after a trial of lead antifungal drug SCY-078 was halted by order of the FDA on safety grounds.